Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Phase 2a Randomized, Part Parallel-group, Double-blind Placebo-controlled Cross-over Multi-center Study to Evaluate the Effect of Two Dose Levels of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass in Obese Patients During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)

NCT07101939 is registered in ClinicalTrials.gov with Actimed Therapeutics Ltd as lead sponsor.

NCT NCT07101939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07101939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Phase 2a Randomized, Part Parallel-group, Double-blind Placebo-controlled Cross-over Multi-center Study to Evaluate the Effect of Two Dose Levels of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass in Obese Patients During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Lead sponsor
Actimed Therapeutics Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
June 23, 2025
Completion date
March 31, 2027
Enrollment
120 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

muscle loss, obesity